“There are so many advances in cardiovascular therapeutics that I think this particular edition is going to bring a richness that hasn’t been seen before.”
Cardiovascular medicine is indeed a very rapidly moving field. I’m particularly attracted to cardiovascular pharmacology. In the Thrombolysis In Myocardial Infarction Study Group that I’m involved in, we’re constantly investigating agents that are potentially helpful for patients with coronary artery disease. We’ve branched out to anti-coagulation for patients with atrial fibrillation in an attempt to reduce their risk of stroke. I’ve seen important interactions between the drugs we prescribe and the devices that we now implant in patients. We’re also in a position now to be doing some very interesting physiologic monitoring of patients. I see a very bright future for those of us who are interested in the science that improves the care of our patients.
Cardiovascular Therapeutics is a companion to Braunwald’s Heart Disease. The concept of a companion textbook was really something that grew out of a vision that Dr. Braunwald had. Heart Disease, which we all view as the bible that we turn to for information on managing patients with cardiovascular disease or planning our research projects, is now in its ninth edition. The companion enables readers to look at a particular topic in greater depth. It covers all the major topical areas in cardiology — heart failure, hypertension, arrhythmias, lipid management, and general cardiology issues, such as management of a pregnant patient or of a patient with endocarditis or pericarditis. It’s been an extremely valuable addition to the armamentarium that readers now have. The fourth edition also includes new advances, particularly in genetics, pharmacogenomics, and proteomics. My colleague Dr. Marc Sabatine is an expert in those areas and is a natural choice to be co-editor of this edition. There are so many advances in cardiovascular therapeutics that I think this particular edition is going to bring a richness that hasn’t been seen before.
This edition of Cardiovascular Therapeutics has moved into the digital age. In the third edition, we had a CD attached to the textbook that gave readers the opportunity to look at the figures in more detail. Now we have a web-based version of the figures and tables so that readers who purchase this textbook will be able to get full access to a digital format that enhances their ability to acquire the information, understand it, and perhaps even use some of those figures in their own talks.
Elliott M. Antman, MD is a senior faculty member in the Cardiovascular Division of the Brigham and Women’s Hospital. He has devoted his career to academic medicine and research, and is recognized for his active role and interest in education and training. He is a co-author of Cardiovascular Therapeutics: A Companion To Braunwald’s Heart Disease, 4th edition.
Dr. Antman is an active member of the American Heart Association and American College of Cardiology, and was the chairman of the joint ACC/AHA Task Force on Practice. He is also a member of the AHA Science and Advisory Coordinating Committee and the Manuscript Oversight Committee, Chair of the Committee on Scientific Sessions Programs, Chair of the Advocacy Coordinating Committee, and a member of the Board of Directors for the AHA. He is the recipient of the Gifted Teacher Award of the ACC, of the Meritorious Achievement Award from the AHA, and Herrick Award from the AHA Clinical Council on Cardiology. Dr. Antman is Associate Dean for Clinical/Translational Research at Harvard Medical School. Internationally, Dr. Antman has been an invited speaker at plenary sessions of the European Society of Cardiology.